[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-071026023--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-071026023","PRESSRELEASE"," OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration","2026-10-07T08:01:24.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> LONDON, Oct. 7, 2026 \u002FPRNewswire\u002F -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetration of tyrosine kinase inhibitors (TKIs).\u003C\u002Fp>\u003Cp> OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are present both on the blood-brain barrier and on tumour cells. The product is being developed as a once-daily oral tablet, which will be used in combination with a number of gold standard oncology treatments in order to optimise their efficacy.\u003C\u002Fp>\u003Cp> In perfused-brain mouse studies, OB-001 pretreatment significantly raised brain exposure of four gold standard kinase inhibitors – whilst systemic (plasma) exposure remained broadly unchanged. Data presented at AACR 2026 demonstrated that OB-001 could increase the brain exposure of osimertinib by almost 400% with minimal systemic changes[1],[2]. Based on a translational PK-PD-TGI model for osimertinib, this increase is projected to deliver a step-change in CNS progression-free survival for EGFRm NSCLC patients. The improved control of brain metastases is still a major area of unmet need in NSCLC and breast cancer.\u003C\u002Fp>\u003Cp> The same efflux pumps have also been identified as a key resistance mechanism impacting ADCs – with the over-expression of these pumps leading to reduced payload concentrations in the tumour. Preclinical work using a bidirectional transporter assay demonstrated that OB-001 reduces efflux for several leading payloads, including SN-38 (e.g. sacituzumab govitecan, Trodelvy®), DM4 (e.g. mirvetuximab soravtansine, Elahere®) and DXd (e.g. trastuzumab deruxtecan, Enhertu®).\u003C\u002Fp>\u003Cp> Plans are currently underway to move into a parallel clinical trial programme to generate POC data in combination with osimertinib, and also evaluate T-DXd re-sensitisation.\u003C\u002Fp>\u003Cp> \"This is a critical milestone for our team, and we are now well positioned to initiate our clinical plans with OB-001\" said Jim Millen, Chief Executive Officer for OncoBayes. \"OB-001 is on track to become a first-in-class drug with broad potential as a simple, oral adjunct to a range of blockbuster oncology therapies. This is truly a pipeline in a product opportunity.\"\u003C\u002Fp>\u003Cp> References: 1. AACR2026 Abstract 5873. 1 April 2026; 86 (7_Supplement): 5873. https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.AM2026-5873 [https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.AM2026-5873].2. Cancer Research Communications 1 May 2026; 6 (5): 1213–1219. \u003Ca target=\"_blank\" href=\"https:\u002F\u002Furldefense.proofpoint.com\u002Fv2\u002Furl?u=https-3A__doi.org_10.1158_2767-2D9764.CRC-2D25-2D0553&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=kuYbvllu4QLn4DTnlHmV7LPO6uFRrVFzjIUm1ucUmpU&m=pc04esVDLwonDxcvKP7Yod3kH1bwhz8Y8UuMh5bdixgcOHZCL_1w9gkRNzV2-OLl&s=epbphPmRmDa55jpgqGmKR882SHrmoDHrHVGJY3fjQ8I&e=\">https:\u002F\u002Fdoi.org\u002F10.1158\u002F2767-9764.CRC-25-0553.\u003C\u002Fa>\u003C\u002Fp>\u003Cp> View original content:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Foncobayes-progressing-ob-001-to-tackle-adc-resistance-and-tki-brain-penetration-302900100.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","LONDON, Oct. 7, 2026 \u002FPRNewswire\u002F -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical",[16,21,26,31,36,41,46,50,55,59],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-071026087"," Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant","2026-10-07T14:31:25.000+02:00","Exclusive partnership results in a user-centric, hydrocarbon-cooled centrifuge purpose-built for clinical trials – years ahead of upcoming F-gas regulatory chan",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-071026070"," Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development","2026-10-07T13:03:24.000+02:00","More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 \u002FPRNewswire\u002F -- Veeva Systems (NYSE: VEEV) toda",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-071026059"," Nestlé and NBA announce multi-year international marketing partnership","2026-10-07T12:01:25.000+02:00","- Milo,Nescau and Nesquikwill become Official Partners of the National Basketball Association (NBA) - The partnership will include activations across select NBA",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-071026032"," Linux Foundation Launches OpenGrid to Build Open, Shared Infrastructure for the World's Electric Grid","2026-10-07T09:12:24.000+02:00","New open source initiative integrates and builds a data platform and tools to accelerate grid planning and energy infrastructure deployments worldwide - The Lin",{"id":37,"title":38,"pubDate":39,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-071026031"," xFusion Joins the Linux Foundation to Support Open Source Innovation","2026-10-07T09:03:25.000+02:00","xFusion will contribute its infrastructure expertise to open source communities across the Linux Foundation PRAGUE, Oct. 7, 2026 \u002FPRNewswire\u002F -- Open Source Sum",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-071026030"," ORTEC mentioned as a Representative Vendor in 2026 Gartner® Market Guide for Vehicle Routing and Scheduling","2026-10-07T09:01:25.000+02:00","ORTEC advances AI-powered planning for more adaptive, resilient logistics operations. ZOETERMEER, Netherlands, Oct. 7, 2026 \u002FPRNewswire\u002F -- ORTEC, a global lead",{"id":47,"title":48,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":49},"CSN-071026029"," Linux Foundation Europe Report Finds Digital Sovereignty Drives European Tech Strategy, but Governance and AI Strain Present Major Hurdles","European organizations report strong returns from open source as AI adoption, regulation and technology sovereignty reshape software strategy PRAGUE, Oct. 7, 20",{"id":51,"title":52,"pubDate":53,"logoUrl":8,"thirdParty":11,"orgId":13,"description":54},"CSN-071026025"," LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show","2026-10-07T08:04:25.000+02:00","- Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma - Showcasing key solutions for factory design, production operations, and quality ",{"id":56,"title":57,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":58},"CSN-071026024"," Market Logic's DeepSights MCP scales market insights reach and business impact through enterprise-wide AI workflows","DeepSights MCP, now generally available, connects an expert market intelligence AI to Microsoft Copilot, ChatGPT, Claude and custom agents, so everyday AI work ",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14}]